Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 19/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16060222 | 0.91 | BRAF (0.55) | BRAFCYP2C9 | |
| SCHEMBL26075614 | 0.87 | BRAF (0.61) | BRAFCYP2C9LMNAGAAMAPT | |
| SCHEMBL2856180 | 0.87 | BRAF (0.61) | BRAFCYP2C9LMNAGAAMAPT | |
| SCHEMBL1697887 | 0.87 | BRAF (0.68) | BRAFCYP2C9 | |
| SCHEMBL5004766 | 0.86 | BRAF (0.59) | BRAFCYP2C9 | |
| Hydrochloric Acid SCHEMBL1697863 | 0.86 | BRAF (0.67) | BRAFCYP2C9 | |
| SCHEMBL1697968 | 0.86 | BRAF (0.59) | BRAFCYP2C9 | |
| SCHEMBL3932173 | 0.85 | BRAF (0.65) | BRAFCYP2C9 | |
| SCHEMBL20577832 | 0.84 | BRAF (0.58) | BRAFCYP2C9RAB9A | |
| SCHEMBL26077928 | 0.84 | BRAF (0.58) | BRAFCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207616-A1 | Quinoxalines as B Baf Inhhibitors | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207616-A1 | Quinoxalines as B Baf Inhhibitors | BRAF, NRAS, ARAF | BRAF 1/4885CYP2C9 1230/4885LMNA 787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.